A video from the international key opinion leader prof. Dr. Petros christopoulos on therapeutic sequencing in ALK+ NSCLC.

The International Key Opinion Leader Prof. Dr. Petros Christopoulos presented key data about “The emerging new paradigm in early-stage NSCLC” and “Optimizing the management of ALK+ NSCLC patients”.

Both presentations were followed by a lively discussion with the three Belgian expert panelists, Dr. Mariana Brandao, Prof. Dr. Paul Germonpré and Prof. Nana Frank Aboubakar.

Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.